Skip to main content

Table 1 Clinical variables in patients with high and low expression of PAR2

From: Increased expression of protease-activated receptors 2 indicates poor prognosis in HBV related hepatocellular carcinoma

Variable

PAR2 expression

P value

Low expression

High expression

 Sample size

63

139

 

 Age, years

  

0.074

  > 50

25 (39.7%)

74 (53.2%)

 

  ≤50

38 (60.3%)

65 (46.8%)

 

Gender

  

0.187

 Male

57 (90.5%)

116 (83.5%)

 

 Female

6 (9.5%)

23 (16.5%)

 

AFP, ng/mL

  

0.067

  < 20

18 (28.6%)

24 (17.3%)

 

  ≥ 20

45 (71.4%)

115 (82.7%)

 

Cirrhosis

  

0.889

 Yes

53 (84.1%)

118 (84.9%)

 

 No

10 (15.9%)

21 (15.1%)

 

Tumor size, cm

  

0.154

  < 5

23 (36.5%)

37 (26.6%)

 

  ≥ 5

40 (63.5%)

102 (73.4%)

 

Differentiation

  

< 0.001

 Well-moderate

22 (34.9%)

12 (8.6%)

 

 Poor-undifferentiated

41 (65.1%)

127 (91.4%)

 

TNM stage

  

0.015

 I–II

42 (66.7%)

67 (48.2%)

 

 III–IV

21 (33.3%)

72 (51.8%)

 

Vascular invasion

  

0.290

 Yes

8 (12.7%)

26 (18.7%)

 

 No

55 (87.3%)

113 (81.3%)

 
  1. Abbreviations: PAR2 proteinase activated receptor 2, AFP alpha-fetoprotein